ArticleLiver cancer2023
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study.
Article in Liver cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Safety and efficacy of salvage surgery for unresectable hepatocellular carcinoma after conversion with triple therapy: a systematic review and meta-analysis of data from Chinese patients.World journal of surgical oncology · 2025Pooled it
- Taiwan liver cancer association management consensus guidelines for intermediate-stage hepatocellular carcinoma.Clinical and molecular hepatology · 2025Guideline
- Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Trial
- Prognostic Value of Pathological Response After Conversion Therapy and Salvage Surgery in Unresectable Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Article
- The efficacy of sequential radiotherapy after the combination of TACE with lenvatinib and anti-PD-1 antibodies for unresectable HCC.The oncologist · 2026Article
- Sequential ICI plus Anti-VEGF/TKI with On-Demand TACE beyond RECIST Progression Improves Pathological Response, Resectability, and Survival in Unresectable HCC.Liver cancer · 2026Article
- Oncological Outcomes Following Different TACE-Based Conversion Therapies for Intermediate-Advanced Hepatocellular Carcinoma.Cancer medicine · 2026Article
- Prognostic Value of the SEA Score in Double-Negative DCP/AFP Unresectable HCC with Triple Therapy.Journal of hepatocellular carcinoma · 2026Article
- The SAGES scoring model leads to personalized treatment via the combination of TACE, TKIs and ICIs for unresectable hepatocellular carcinoma.Frontiers in immunology · 2026Article
- AADN score: Predicting response to transarterial chemoembolization, sintilimab and lenvatinib in patients with hepatocellular carcinoma.World journal of gastroenterology · 2025Article
- Integrated ultrasound radiomics and clinical data to predict PD-1 blockade efficacy in unresectable hepatocellular carcinoma.BMC gastroenterology · 2025Article
- Intra-arterial lidocaine improves long-term survival in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolisation. Response to Br J Anaesth 2025; 135: 509-10.British journal of anaesthesia · 2025Article
- Are we overestimating success of salvage hepatectomy in unresectable hepatocellular carcinoma?World journal of clinical oncology · 2025Article
- Prognostic Impact of the Pathologic Response of Patients with Hepatocellular Carcinoma After Preoperative Treatments.Annals of surgical oncology · 2025Article
- Prognostic Value of Clinical Complete Response for Patients with Initially Unresectable Hepatocellular Carcinoma after Conversion with Triple Therapy.Liver cancer · 2025Article
- ASO Author Reflections: Stage-Specific Tumor Residual Thresholds Following Preoperative Therapies in Hepatocellular Carcinoma: Prognostic Implications and Tailored Management Strategies.Annals of surgical oncology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The actual rate of conversion surgery and its prognostic advantages remain unclear. This study aimed to assess the outcomes of salvage surgery after conversion therapy with triple therapy (transcatheter arterial chemoembolization [TACE] combined with lenvatinib plus anti-PD-1 antibodies) in patients with initially unresectable hepatocellular carcinoma (uHCC). Methods: Patients with initially uHCC who received at least one cycle of first-line triple therapy and salvage surgery at five major cancer centers in China were included. The primary endpoints were overall survival (OS) and recurrence-free survival (RFS) rates after salvage surgery. The secondary endpoints were perioperative complications, 90-day mortality, and pathological tumor response. Results: Between June 2018 and December 2021, 70 patients diagnosed with uHCC who underwent triple therapy and salvage surgery were analyzed: 39 with Barcelona Clinic Liver Cancer (BCLC) stage C, 22 with BCLC stage B, and 9 with BCLC stage A disease. The median interval between the start of triple therapy and salvage surgery was 4.3 months (range, 1.7-14.2 months). Pathological complete response and major pathological response were observed in 29 (41.4%) and 59 (84.3%) patients, respectively. There were 2 cases of perioperative mortality (4.3%) and 5 cases of severe perioperative complications (7.1%). With a median follow-up of 12.9 months after surgery (range, 0.3-36.8 months), the median OS and RFS were not reached. The 1- and 2-year OS rates were 97.1% and 94.4%, respectively, and the corresponding RFS rates were 68.9% and 54.4%, respectively. Conclusion: First-line combination of TACE, lenvatinib, and anti-PD-1 antibodies provides a better chance of conversion therapy in patients with initially uHCC. Furthermore, salvage surgery after conversion therapy is effective and safe and has the potential to provide excellent long-term survival benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.